Birnin Shanghai ya kaddamar da magungunan gargajiya na kasar Sin da kuma shirye-shirye masu sauki da marasa magani don taimakawa mutane yaki da mura

1.Shanghai ya kaddamar da magungunan gargajiya na kasar Sin da kuma shirye-shirye masu sauki da marasa magani don taimakawa mutane yaki da mura.

Hukumar kula da magungunan gargajiyar kasar Sin ta birnin Shanghai ta bayyana a ran 5 ga wata cewa, cibiyar yaki da cututtuka ta kasar Sin (Shanghai) ta jagoranci tsara shirin rigakafin cutar mura da cutar murar bazara ta shekarar 2023 a birnin Shanghai. (nan gaba ana kiranta da shirin), ya ba da shawarar fahimtar likitancin kasar Sin game da mura, da samar da magungunan likitancin kasar Sin ga manya da yara bisa la'akari da bambance-bambancen cututtuka, da kuma kaddamar da wasu magunguna na gargajiya na kasar Sin da dama da shirye-shirye masu sauki da marasa magani don rigakafi da sarrafa mura. .

A lokacin hunturu da bazara, yanayi yana da zafi da sanyi, bambancin zafin jiki tsakanin dare da rana yana canzawa, kuma cututtuka na lokaci-lokaci sun shiga cikin lokaci mai yawa da annoba.Kwanan nan, adadin masu fama da mura A da sauran cututtuka da manyan asibitocin birnin Shanghai suka samu ya karu.Shirin na da nufin ba da cikakkiyar wasa ga halaye da fa'idar magungunan gargajiyar kasar Sin wajen yin rigakafi da maganin mura.

Zhang Wei, daya daga cikin mawallafin shirin, mataimakin shugaban kungiyar kwararru ta COVID-19 mai kula da magungunan gargajiya na kasar Sin, kuma darektan sashen cututtukan huhu na asibitin Shuguang, ya yi imanin cewa, kamuwa da mura (mura) galibi kansa ne. iyakance.Wasu yara masu rauni da tsofaffi masu fama da cututtuka na iya haifar da wasu rikice-rikice saboda cututtuka na waje, wanda shi ne abin da aka mayar da hankali kan rigakafi da kula da magungunan gargajiya na kasar Sin da magungunan yammacin Turai.Ya shaida wa manema labarai cewa, magungunan gargajiya na kasar Sin sun yi imanin cewa mura na cikin nau'in sanyi na yanzu.A bisa fahimtar al'ada, ganewar asali da magani sun fi dogara ne akan tsarin bambance-bambancen ciwo da kuma hanyoyin magance cututtuka na meridians shida, bambance-bambancen ciwo na Weiqi da Yingxue, da tsarin bambance-bambancen ciwo da tsarin maganin jiao guda uku, da hankali. an biya shi zuwa aikace-aikacen haɗin gwiwa na ƙarfafawa da kawar da abubuwan pathogenic ta matakai da matakai.

"Mura yawanci yana iyakance kansa kuma ana iya warkewa a cikin ɗan gajeren lokaci bayan jiyya ta gabaɗaya da sa hannun TCM."Zhang Wei ya yi nuni da cewa, baya ga magungunan gargajiya na kasar Sin, da shirye-shirye masu sauki da aka ba da shawarar a cikin shirin, manyan asibitocin TCM da ke birnin Shanghai na da kwarewa sosai wajen tantance cutar mura, da kuma jerin shirye-shiryen asibitoci da rubutaccen magani.

An ba da rahoton cewa watsawar kwanan nan galibi H1N1 ne.Idan aka kwatanta da mura, yana da saurin yaɗuwa, yana da zazzabi mai girma kuma yana daɗe, yana da bayyanar cututtuka na tsari, kuma yana da tsawon lokaci na cututtuka.

Xue Zheng, marubucin shirin yara, kuma darektan sashen kula da lafiyar yara na asibitin gundumar birnin Shanghai na likitancin gargajiya na kasar Sin, ya yi imanin cewa, yara 'yan kasa da shekaru 5 suna kamuwa da mura.Yara suna kamuwa da mura kuma suna da alamun cututtuka masu tsanani saboda lallausan huhunsu.Magungunan gargajiya na kasar Sin suna taka rawa sosai wajen rigakafi da magance cutar mura a yara, musamman wajen maganin mura, wanda zai iya hana yaduwar cutar da zurfin kwayar cutar, da saurin saurin bayyanar cututtuka, kuma yana da fa'ida.Likitocin yara a manyan asibitocin kasar Sin da na Yamma suma suna da manyan shirye-shiryen asibiti da ake amfani da su a asibiti.

Shirin ya tsara takardar yarjejeniyar magungunan gargajiya ta kasar Sin, da magunguna na gargajiya na kasar Sin, da kuma shirye-shirye masu sauki na maganin mura na yara, da kuma ba da shawarar wasu hanyoyi masu sauki da rahusa na maganin gargajiya na kasar Sin.Iyaye za su iya aiwatar da aikin ba da magani na gargajiya na kasar Sin ta hanyoyin jiyya na waje kamar su jiyya na abinci, tausa, maki kunne, aikace-aikace da turaren turare don taimakawa yara su inganta bayyanar cututtuka da sauri da kuma dawo da lafiya da wuri-wuri.

2.Scientific masu bincike gano jerin anti-hepatoma aiki sinadaran daga magani shuka Artemisia annua.

Cibiyar Nazarin Botany ta Kunming, Cibiyar Nazarin Kimiyya ta kasar Sin, ta sanar a ranar 21 ga wata cewa, tawagar binciken Chen Jijun ta gano jerin litattafan litattafan litattafai na sesquiterpene dimers tare da maganin cutar kansar hanta daga shukar Artemisia scoparia na magani.An buga sakamakon binciken da ya dace a kwanan nan a cikin shahararren mujallar siginar watsawa da farfagandar Niyya.

Ciwon daji na hanta cuta ce mai muni da ke yin barazana ga lafiyar ɗan adam sosai.A kowace shekara, adadin sabbin masu kamuwa da cutar kansar hanta a duniya ya zarce 840000, kuma adadin wadanda suka mutu sakamakon cutar kansar hanta ya kai 780000, yayin da kusan kashi 50% na sabbin masu kamuwa da cutar ke faruwa a kasar Sin.A halin yanzu, akwai inhibitors na tyrosine kinase guda hudu, sorafenib, regafinil, lovatinib da cabotinib, daya daga cikin jijiyoyin endothelial girma factor receptor 2 antagonist, ramolumab, da kuma masu hana PD-1 guda biyu, navumab da pamuzumab, waɗanda ake amfani da su a cikin maganin ciwon daji na hanta. , amma nau'in tsarin yana da sauƙi mai sauƙi kuma mai sauƙi don samar da juriya na miyagun ƙwayoyi.

A cikin 'yan shekarun nan, ƙungiyar bincike ta Chen Jijun ta himmatu wajen nemo mahaɗan gubar hepatoma da sabbin magungunan da ke da tsari na musamman da kuma sabon tsarin aiki daga tsire-tsire na Artemisia, kuma sun sami nasarar kafa hanyar rabuwa tare da fahimtar jagora na sesquiterpene dimers a Artemisia. shuke-shuke tare da bin diddigin ayyukan anti-hepatoma.Wannan binciken ya gano a karon farko cewa tsantsa daga Artemisia annua yana da aikin hanawa mai ƙarfi akan ƙwayoyin hepatoma guda uku, kuma a karon farko, 36 novel sesquiterpene dimers na nau'ikan tsarin 9 - Artemisia annua A1-A3, B1-B2, C1-C4 , D, E, F1-F15, G1-G8, H kuma an keɓe ni daga sashin aiki na Artemisia annua.

Ci gaba da karatu ya nuna cewa a cikin 36 novel sesquiterpene dimers, aikin artemisinin G5 da G7 shine mafi kyau, wanda yayi daidai da layin farko na maganin hepatoma na sorafenib;Bugu da ƙari, kudancin artemisinin G7 ya nuna mafi kyawun zaɓi da aminci fiye da sorafenib don THLE-2 a cikin ƙwayoyin hanta na al'ada;A lokaci guda kuma, kudancin artemisinin G7 na iya hana yaduwar kwayoyin HepG2 ta hanyar hana mamayewa da ƙaura na ƙwayoyin hepatoma, haifar da apoptosis da kuma toshe zagaye na G2 / M.

Wannan binciken ya bayyana a karon farko jerin sesquiterpene dimers tare da sabon kwarangwal da tsarin daban-daban a cikin Artemisia annua, ya wadatar da tsarin nau'ikan sesquiterpene dimers a cikin tsire-tsire na Artemisia, kuma ya ba da nau'ikan ƙwayoyin ɗan takara da mahimman tushen pharmacological don bincike na sabon maganin rigakafin. - magungunan hepatoma.

Har zuwa yau, ƙungiyar bincike ta Chen Jijun ta keɓe kuma ta gano 122 novel sesquiterpenoid dimers tare da ayyukan anti-hepatoma daga Artemisia australis, Artemisia sinica, Artemisia medinalis, Artemisia cowtail da Artemisia mongolica, lissafin 52% na jimlar adadin 234 sequiterpeno. Artemisia shuke-shuke a duniya.

JinDun Medicalyana da haɗin gwiwar bincike na kimiyya na dogon lokaci tare da fasahar kere-kere tare da jami'o'in kasar Sin.Tare da wadataccen albarkatun kiwon lafiya na Jiangsu, tana da dangantakar kasuwanci ta dogon lokaci tare da Indiya, kudu maso gabashin Asiya, Koriya ta Kudu, Japan da sauran kasuwanni.Hakanan yana ba da sabis na kasuwa da tallace-tallace a cikin gabaɗayan tsari daga matsakaici zuwa ƙãre samfurin API.Yi amfani da tarin albarkatun Yangshi Chemical a cikin sinadarai na fluorine don samar da sabis na keɓance sinadarai na musamman ga abokan haɗin gwiwa.Samar da sabbin abubuwa da ayyukan bincike na ƙazanta don ƙaddamar da abokan ciniki.

JinDun Medical ya nace akan ƙirƙirar ƙungiyar tare da mafarkai, yin samfuran tare da mutunci, ƙwarewa, tsauri, da fita gabaɗaya don zama amintaccen abokin tarayya da abokin abokan ciniki!Masu samar da mafita guda ɗaya, R&D na musamman da sabis na samarwa na musamman don matsakaicin magunguna da APIs, sana'amusamman samar da magunguna(CMO) da R&D na Pharmaceutical na musamman da masu samar da sabis (CDMO).